# Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4
Ticker: STIM
Company: Neuronetics
Source: Neuronetics
Published: 2026-04-29 20:30 EST
Original Source URL: https://ir.neuronetics.com
## Summary

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting

## Article Body
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting
## Recent Company News
- 2026-06-02 20:30 EST — [Neuronetics Appoints Robert Greene as Senior Vice President Sales](https://biopharmsignal.com/news/STIM/neuronetics-appoints-robert-greene-as-senior-vice-president-sales) — Source: Neuronetics
- 2026-06-02 12:32 EST — [Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026](https://biopharmsignal.com/news/STIM/neuronetics-highlights-continued-advancements-in-tms-research-at-ctmss-2026) — Source: Neuronetics
- 2026-05-14 12:32 EST — [Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment](https://biopharmsignal.com/news/STIM/neuronetics-and-ant-neuro-announce-strategic-collaboration-to-integrate-neuronavigation-with-neurostar-tms-treatment) — Source: Neuronetics
- 2026-05-05 11:50 EST — [Neuronetics Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/STIM/neuronetics-reports-first-quarter-2026-financial-and-operating-results) — Source: Neuronetics
- 2026-04-29 20:30 EST — [Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/STIM/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Neuronetics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)